(Q33366883)

26 July 2017

title

Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma (English)

1 reference

26 July 2017

1 reference

1 reference

3

Barbara Pro

0 references

author name string

Yasuhiro Oki

1

1 reference

26 July 2017

Peter McLaughlin

2

1 reference

26 July 2017

Barbara Pro

3

1 reference

26 July 2017

Fredrick B Hagemeister

4

1 reference

26 July 2017

Archie Bleyer

5

1 reference

26 July 2017

Evelyn Loyer

6

1 reference

26 July 2017

Anas Younes

7

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

26 July 2017

1 reference

26 July 2017

volume

104

1 reference

26 July 2017

issue

4

1 reference

26 July 2017

page(s)

781-787

1 reference

26 July 2017

cites work

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21219

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.21219

1 reference

7 January 2021

Oxaliplatin-safety profile: neurotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21219

7 January 2021

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21219

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21219

7 January 2021

Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21219

7 January 2021

Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: a study of the cancer and acute leukemia group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21219

7 January 2021

An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21219

7 January 2021

Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21219

7 January 2021

Gemcitabine and oxaliplatinum: an effective regimen in a patient with progressive refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21219

7 January 2021

Identifiers

DOI

10.1002/CNCR.21219

1 reference

26 July 2017

1 reference